KLTO - Klotho Neurosciences, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
0.63 0.02 (3.17%)	---	0.0 (0.0%)	0.01 (0.92%)	-0.01 (-2.1%)	0.04 (6.44%)	-0.01 (-1.07%)	-0.01 (-1.07%)

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.12
Diluted EPS:: -0.12
Basic P/E:: -5.4167
Diluted P/E:: -5.4167
RSI(14) 1m:: 100.0
VWAP:: 0.65
RVol:: 1.0867

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	0.67 +0.01 (+1.2%)	Oct 15 17:40
1m	Price increase 1m	0.65 +0.01 (+1.06%)	Oct 15 13:43
1m	Price decrease 1m	0.64 -0.01 (-1.03%)	Oct 15 13:42
1m	Price increase 1m	0.66 +0.01 (+1.11%)	Oct 15 13:38
1m	Price decrease 1m	0.65 -0.01 (-1.98%)	Oct 15 12:27